Clinical Trial Update: Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating daclizumab (Zenapax) for relapsing-remitting multiple sclerosis has completed, according to an NINDS-sponsored study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Zenapax (daclizumab)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Status: COMPLETED